{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:40:58Z","timestamp":1776300058885,"version":"3.50.1"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.bmcl.2022.129081","type":"journal-article","created":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T02:16:11Z","timestamp":1668824171000},"page":"129081","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Design, synthesis and biological evaluation of cajanonic acid A analogues as potent PPAR \u03b3 antagonists"],"prefix":"10.1016","volume":"80","author":[{"given":"Xiao-Ting","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Ying","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Juan","family":"Ban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bi-Lan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gao-Feng","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-Pei","family":"Sang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-Ta","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2022.129081_b0005","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1021\/acs.jmedchem.5b01239","article-title":"N-Benzylbenzamides: a novel merged scaffold for orally available dual soluble epoxide hydrolase\/peroxisome proliferator-activated receptor \u03b3 modulators","volume":"59","author":"Bl\u00f6cher","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2022.129081_b0010","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/978-3-030-78315-0_21","article-title":"PPAR modulation through posttranslational modification control","author":"Videira","year":"2021","journal-title":"Nucl Receptors"},{"key":"10.1016\/j.bmcl.2022.129081_b0015","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.bbapap.2017.03.008","article-title":"Structural basis for differential activities of enantiomeric PPAR \u03b3 agonists: Binding of S35 to the alternate site","volume":"1865","author":"Jang","year":"2017","journal-title":"Biochim Biophys Acta (BBA)-Proteins and Proteomics"},{"key":"10.1016\/j.bmcl.2022.129081_b0020","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/466443a","article-title":"Obesity: New life for antidiabetic drugs","volume":"466","author":"Houtkooper","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.bmcl.2022.129081_b0025","first-page":"7","article-title":"Re-highlighting the action of PPAR \u03b3 in treating metabolic diseases","author":"Choi","year":"2018","journal-title":"F1000Research"},{"key":"10.1016\/j.bmcl.2022.129081_b0030","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1001\/jama.2010.920","article-title":"Risk of acute myocardial infarction, stroke, heart failure, and death in elderly medicare patients treated with rosiglitazone or pioglitazone","volume":"304","author":"Graham","year":"2010","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.bmcl.2022.129081_b0035","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1080\/14656566.2020.1853100","article-title":"Are thiazolidinediones a preferred drug treatment for type 2 diabetes?","volume":"22","author":"Hurren","year":"2021","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.bmcl.2022.129081_b0040","series-title":"Thiazolidinediones","author":"Eggleton","year":"2021"},{"key":"10.1016\/j.bmcl.2022.129081_b0045","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/nature10383","article-title":"Antidiabetic actions of a non-agonist PPAR \u03b3 ligand blocking Cdk5-mediated phosphorylation","volume":"477","author":"Choi","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.bmcl.2022.129081_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.101030","article-title":"The therapeutic potential of inhibiting PPAR \u03b3 phosphorylation to treat type 2 diabetes","volume":"297","author":"Frkic","year":"2021","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmcl.2022.129081_b0055","doi-asserted-by":"crossref","first-page":"4027","DOI":"10.1021\/jm101360s","article-title":"Targeting peroxisome proliferator-activated receptors (PPARs): development of modulators","volume":"55","author":"Pirat","year":"2012","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2022.129081_b0060","doi-asserted-by":"crossref","first-page":"9272","DOI":"10.1039\/C5CP06729D","article-title":"PPAR \u03b3 helix 12 exhibits an antagonist conformation","volume":"18","author":"Fratev","year":"2016","journal-title":"PCCP"},{"key":"10.1016\/j.bmcl.2022.129081_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2021.116368","article-title":"Virtual screening and biological evaluation of PPAR \u03b3 antagonists as potential anti-prostate cancer agents","volume":"46","author":"Almahmoud","year":"2021","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmcl.2022.129081_b0070","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1021\/acschembio.6b01015","article-title":"Modification of the orthosteric PPAR\u03b3 covalent antagonist scaffold yields an improved dual-site allosteric inhibitor","volume":"12","author":"Brust","year":"2017","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.bmcl.2022.129081_b0075","unstructured":"Qiu S, Shen X. Natural drug of cajanonic acid A with hypoglycemic and slimming function., CN 101422450 B."},{"key":"10.1016\/j.bmcl.2022.129081_b0080","unstructured":"Shen X, Hu Y, Qiu S, et al. Medicament useful for reducing blood sugar and body weight having the structure of stilbene compounds. WO 2013013417 A1."},{"key":"10.1016\/j.bmcl.2022.129081_b0085","first-page":"189","article-title":"Inhibitory effect of cajanonic acid A on lipogenesis and lipolysis in 3 T3\u2013L1 adipocytes","volume":"2","author":"Qin","year":"2016","journal-title":"Chin Pharmacol Bull"},{"key":"10.1016\/j.bmcl.2022.129081_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2021.128410","article-title":"Synthesis and biological evaluation of cajanonic acid A derivatives as potential PPAR \u03b3 antagonists","volume":"52","author":"Wang","year":"2021","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmcl.2022.129081_b0095","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/j.str.2018.07.007","article-title":"Chemical crosslinking mass spectrometry reveals the conformational landscape of the activation helix of PPAR \u03b3, a model for ligand-dependent antagonism","volume":"26","author":"Zheng","year":"2018","journal-title":"Structure"},{"key":"10.1016\/j.bmcl.2022.129081_b0100","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.isci.2018.06.012","article-title":"PPAR \u03b3 in complex with an antagonist and inverse agonist: a tumble and trap mechanism of the activation helix","volume":"5","author":"Frkic","year":"2018","journal-title":"IScience."},{"key":"10.1016\/j.bmcl.2022.129081_b0105","doi-asserted-by":"crossref","first-page":"16548","DOI":"10.1002\/chem.201804734","article-title":"Ruthenium (IV) intermediates in C\u2013H activation\/annulation by weak O-coordination","volume":"24","author":"Liang","year":"2018","journal-title":"Chem Eur J"},{"key":"10.1016\/j.bmcl.2022.129081_b0110","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1055\/s-1989-27225","article-title":"Dealkylation of activated alkyl aryl ethers using lithium chloride in dimethylformamide","volume":"1989","author":"Bernard","year":"1989","journal-title":"Synthesis"},{"key":"10.1016\/j.bmcl.2022.129081_b0115","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1016\/S0040-4039(00)89033-4","article-title":"Clay catalyzed rearrangement of substituted allyl phenyl ethers: Synthesis of ortho-allyl phenols, chromans and coumarans","volume":"31","author":"Dauben","year":"1990","journal-title":"Tetrahedron Lett"},{"key":"10.1016\/j.bmcl.2022.129081_b0120","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1074\/jbc.275.3.1873","article-title":"A synthetic antagonist for the peroxisome proliferator-activated receptor \u03b3 inhibits adipocyte differentiation","volume":"275","author":"Wright","year":"2000","journal-title":"J Biol Chem"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X22005571?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X22005571?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T07:46:08Z","timestamp":1760773568000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X22005571"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":24,"alternative-id":["S0960894X22005571"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2022.129081","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis and biological evaluation of cajanonic acid A analogues as potent PPAR \u03b3 antagonists","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2022.129081","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"129081"}}